Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease

NCT01485055 is registered in ClinicalTrials.gov with Nationwide Children's Hospital as lead sponsor.

NCT NCT01485055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01485055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
Lead sponsor
Nationwide Children's Hospital
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2011
Completion date
September 26, 2016
Enrollment
11 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute gvh disease, graft versus host disease, steroid refractory gvhd